Zimbabwe has rejected a significant US healthcare agreement worth $367m (272 million pounds) spanning five years over the United States' demand for confidential biological samples.
This rejection came to light after a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesperson later stated that the US was requesting health data for research and profit but was unwilling to share the resulting advantages from future medical innovations.
"We are forced to start the difficult and regrettable task of scaling back our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had furnished more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for more negotiations to reach a agreement agreeable to all parties so the country's critical HIV programme can proceed.
Broader Background
This development comes after a comparable situation in neighbouring Kenya, where a high court blocked a similar deal with the US after concerns were filed about the security of citizens' medical information.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government deals to boost openness and accountability.
According to statements, 16 nations in Africa have so far signed these new health pacts, constituting over $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership would have delivered significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Our nation was requested to surrender its biological resources and data over an extended period, without any corresponding promise of benefiting from any scientific breakthroughs – like new medicines or tests – that might result from that provided information," his statement read.
"Effectively, our country would supply the raw materials for scientific discovery with no assurance that the final treatments would be available to our population should a new pandemic arise."
Sovereignty and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining systems previously established via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing scheme designed to deal with potential pandemics.
"This system is intended to guarantee that when a nation provides its information, the resulting advantages – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as opposition to America," he added.
"We are open to ongoing dialogue with our American counterparts on how future collaboration might be structured in a manner that respects the independence and interests of each country."
Health Experts Reaction
A leading public health body said it acknowledged the official position, but recommended that talks should continue given that much of the nation's Aids initiatives relied on foreign aid.
"In cases where specific concerns exist, such as those relating to information security or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," it added.
This impasse emphasises the complex challenges between accepting much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.